Contents
Key findings
- 1Cerebrolysin is a mixture of small peptides derived from pig brain, given by IV, and used abroad for stroke and dementia.
- 2It has real randomized trials - more than most peptides - and is approved in many countries, though not by the FDA.
- 3A Cochrane review of vascular dementia trials found possible improvements in cognition, but with high risk of bias and effects that may be too small to matter.
- 4A large trial cast doubt on its usefulness for most stroke patients, with possible benefit only in severe cases.
- 5It appears safe short-term, but the evidence for real benefit is weaker than the marketing suggests.
Evidence level
Cerebrolysin has real randomized trials and is approved in many countries for stroke and dementia. But a Cochrane review found the trials had high risk of bias, and concluded any benefit for vascular dementia may be too small to be clinically meaningful.
Regulatory status
Cerebrolysin is approved as an intravenous treatment for stroke, brain injury and dementia in many European and Asian countries, but it is not FDA-approved in the United States.
Cerebrolysin is one of the more legitimate-sounding brain peptides - it is an actual approved medicine in many countries, with real randomized trials behind it. That already puts it ahead of most "nootropic" peptides. The honest twist is that when independent reviewers looked closely at those trials, the evidence turned out to be weaker than the reputation.
What cerebrolysin is
Cerebrolysin is not a single peptide - it is a mixture of small peptides and amino acids made from pig brain tissue. It is given by IV infusion, usually in courses, and is used abroad on the theory that it acts like the brain's own growth and repair signals (neurotrophic factors).
It is approved in many European and Asian countries for stroke, traumatic brain injury, and dementia - but it is not FDA-approved in the United States.
What the evidence actually shows
Vascular dementia. This is cerebrolysin's best-studied use. A randomized, placebo-controlled multicenter trial reported improved clinical outcomes[2]. But the more important document is the Cochrane review - an independent analysis of all the trials together. It found that cerebrolysin might improve cognition and function, but the trials had high risk of bias, the results were inconsistent, and any real benefit may be too small to be clinically meaningful[1].
That is a crucial distinction: "some trials looked positive" is not the same as "the evidence holds up when examined carefully." For cerebrolysin, it partly does not.
Stroke. Results are mixed. A large trial cast doubt on cerebrolysin's usefulness for most stroke patients, with possible benefit only in severe cases.
Alzheimer's disease. Some trials suggest small improvements, but again the evidence is limited.
The honest grade
Cerebrolysin sits in an interesting spot: more evidence than most peptides, but evidence that independent reviewers rate as weak. It is approved abroad and appears safe short-term, but "approved in some countries" and "proven to clearly work" are not the same thing - and the FDA has not approved it at all.
The bottom line
Cerebrolysin is a genuine medicine used around the world, with real trials - which makes it more serious than most peptides marketed for the brain. But the honest reading of those trials, from independent reviewers, is "weak evidence, possibly too small to matter." Interesting and approved abroad; not the proven brain-repair treatment it is sometimes sold as.
Where to go next
- Best peptides for focus and cognition
- Cognitive research hub
- How to read peptide research
- FDA-approved, off-label, investigational and unapproved peptides
Frequently asked questions
- What is cerebrolysin?
- Cerebrolysin is a mixture of small peptides made from pig brain tissue, given by intravenous infusion. It is used in many countries as a treatment for stroke, traumatic brain injury and dementia, on the idea that it protects and supports brain cells.
- Does cerebrolysin actually work?
- It has real randomized trials, and it is approved abroad - but the evidence is weaker than it sounds. A Cochrane review found the vascular dementia trials had high risk of bias, and any benefit may be too small to be clinically meaningful. For stroke, a large trial cast doubt except perhaps in severe cases.
- Is cerebrolysin FDA-approved?
- No. Cerebrolysin is approved in many European and Asian countries, but it is not FDA-approved in the United States.
- Is cerebrolysin safe?
- It appears reasonably safe for short-term use in the trials done so far, with no clear safety signal. But it is an injected biological product not regulated by the FDA, and long-term data is limited.
References
Numbered in order of first use. Study type is shown for every source; see our methodology for how we rank evidence.
- 1.
Cerebrolysin for vascular dementia Cochrane Database of Systematic Reviews (PubMed 23440834), 2013.
Systematic review
Result: Cochrane review of randomized trials of cerebrolysin in vascular dementia found possible improvements in cognition and global function, but the trials had high risk of bias and heterogeneity; any benefit may be too small to be clinically meaningful.
↑ back to text - 2.
Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial Journal of the Neurological Sciences (PubMed 20656516), 2010.
Randomized controlled trial
Result: A randomized, double-blind, placebo-controlled multicenter trial reported improvement in clinical outcomes with cerebrolysin in patients with vascular dementia.
↑ back to text
Review status: Editorially reviewed against primary sources. This article was fact-checked against the primary sources listed in the references by our editorial team, and it has not been reviewed by a licensed clinician. It is educational content, not medical advice. Read our editorial policy and methodology. Spotted an error? Tell us.
